| Cas No.: | 1430114-34-3 |
| Chemical Name: | Unii-vwj4vvz3OU |
| Synonyms: | VWJ4VVZ3OU;GTPL9884;BDBM349975;(S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1h-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;BMS962212;US10208021, Example 184;compound 55 [PMID: 29077405];Benzoic acid, 4-((((1S)-2-((2E)-3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)-1-oxo-2-propen-1-yl)-1,2,3,4-tetrahydro-5-(4-met;Unii-vwj4vvz3OU;BMS-962212 |
| SMILES: | ClC1=CC=C(C(=C1F)/C=C/C(N1CCC2C(=CC=CC=2[C@H]1C(NC1C=CC(C(=O)O)=CC=1)=O)N1C(CN(C)CC1)=O)=O)N1C=NN=N1 |
| Formula: | C32H28ClFN8O5 |
| M.Wt: | 659.066728591919 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | BMS-962212 is a potent, highly selective and reversible small molecule coagulation Factor XIa (FXIa) inhibitor with Ki of 0.7 nM; displays an excellent protease selectivity profile, including thrombin, Factor Xa/VIIa/IXa/XIIa, plasma or tissue kallikrein; shows excellent preclinical efficacy in thrombosis models and aqueous solubility suitable for intravenous administration.ThrombosisPhase 1 Clinical |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
